Article

Predominance of BRCA2 mutation and estrogen receptor-positive breast cancer among BRCA1/2 mutation carriers.

2022-02-11

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> PARP inhibitor (PARPi) agents can improve progression-free survival of patients with breast cancer (BC) who carry a germline <italic>BRCA1</italic> or <italic>BRCA2</italic> pathogenic or likely pathogenic variant (gBRCA1/2) in both the metastatic and adjuvant setting. Therefore, we need to redefine the criteria of women and tumor phenotype that should be tested...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e61e4d03-fb96-5944-811c-6ddbfe6cf0e7
DOI: 10.21203/rs.3.rs-1301478/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Predominance of BRCA2 mutation and estrogen receptor-positive breast cancer among BRCA1/2 mutation carriers.DOI 10.21203/rs.3.rs-1301478/v1Read

Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 MutationSemantic proximity Read

Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological TherapiesSemantic proximity Read

Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?Semantic proximity Read

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and BeyondSemantic proximity Read

Biological Therapies Beyond PARP-Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 MutationsSemantic proximity Read

Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency SignatureSemantic proximity Read

BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies.Semantic proximity Read

Real-World Germline BRCA Testing, Poly(ADP-ribose) Polymerase Inhibitor Utilization, and Survival Outcomes in Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast CancerSemantic proximity Read

Prevalence of tumor genomic alternations in homologous recombination genes among Taiwanese breast cancersSemantic proximity Read

Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR studySemantic proximity Read

Stumbling Blocks on the Path to Personalized Medicine in Breast Cancer: The Case of PARP Inhibitors for <i>BRCA1/2</i>-Associated CancersSemantic proximity Read

A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients.Semantic proximity Read